Use of peroxisome proliferator activated receptor (PPAR)-γ ligands as a treatment for pituitary tumors and associated conditions, such as Cushing's syndrome
AssigneeCedars-Sinai Medical Center
InventorsAnthony P. Heaney, Shlomo Melmed
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for treating a pituitary tumor in a mammal, employing the administration of a peroxisome proliferator activated receptor gamma ligand (also known as “peroxisome proliferating-activator receptor gamma” or “PPAR-γ”). In some embodiments, the peroxisome proliferator activated receptor gamma ligand is a thiazolidinedione compound. Also disclosed are methods for preventing the formation of a pituitary tumor in a mammal and for preventing the recurrence of a pituitary tumor in a mammal. Further disclosed is a method for treating a mammal exhibiting one or more symptoms of Cushing's syndrome.
Claims15
A method for treating a non-cancerous pituitary tumor in a mammal, comprising:
- administering to a mammal having a non-cancerous pituitary tumor an effective amount of at least one peroxisome proliferator activated receptor gamma ligand.
A method for preventing the formation of a non-cancerous pituitary tumor in a mammal, comprising:
- administering to a mammal at higher than normal risk for developing a non-cancerous pituitary tumor an effective amount of at least one peroxisome proliferator activated receptor gamma ligand.
A method for preventing the recurrence of a non-cancerous pituitary tumor in a mammal, comprising:
- administering to a mammal, said mammal previously having had a detectable, non-cancerous pituitary tumor that was eliminated, an effective amount of at least one peroxisome proliferator activated receptor gamma ligand, whereby recurrence of the non-cancerous pituitary tumor is prevented.
A method for treating a mammal exhibiting one or more symptoms of Cushing's syndrome resulting from hypersecretion of adrenocorticotrophic hormone (ACTH), comprising:
- administering to the mammal an effective amount of at least one peroxisome proliferator activated receptor gamma ligand.
A method for treating a non-functioning, non-cancerous pituitary tumor in a mammal, comprising:
- administering to a mammal having a non-functioning, non-cancerous pituitary tumor an effective amount of at least one peroxisome proliferator activated receptor gamma ligand.
A method for treating a non-functioning, non-cancerous pituitary tumor in a mammal, comprising administering to a mammal having a non-functioning, non-cancerous pituitary tumor an effective amount of a thiazolidinedione compound.
A method for treating a non-functioning, non-cancerous pituitary tumor in a mammal, comprising:
- administering to a mammal having a non-functioning, non-cancerous pituitary tumor an effective amount of a thiazolidinedione compound selected from the group consisting of rosiglitazone, pioglitazone, and troglitazone.
Dependencies are inferred from the claim text.